Analyst Viewpoint
Growth in awareness about benefits of aptamer over antibodies is encouraging healthcare professionals to use aptamer-based therapies as a key treatment option to reduce recovery time. Aptamers are extensively employed in cancer treatments to deliver the drug to precise targeted cells. Increase in prevalence of cardiovascular and chronic diseases is driving the aptamer market value.
Rise in availability of healthcare facilities for chronic diseases in developing regions is also fueling market dynamics. Furthermore, increase in number of clinical trials conducted by healthcare organizations helps in research and development of novel treatments. In line with the latest aptamer market trends, key players are striving to introduce advanced treatments in order to increase their industry share.
Aptamer is a special class of nucleic acid molecule that is being investigated for clinical use. It is a short, single-stranded DNA or RNA molecule that can selectively bind to particular targets such as live cells, carbohydrates, peptides, toxins, small molecules, and proteins. These small RNA/DNA molecules can form tertiary and secondary structures capable of precisely binding proteins or other cellular targets and are equivalent to antibodies.
Aptamers are formed through an iterative selection process known as Systematic Evolution of Ligands by exponential enrichment (SELEX) by using single-stranded DNA or RNA. Aptamers are bound with nucleic acid macromolecules with specificity and high affinity.
Aptamers have a longer shelf life and are more stable than antibodies. They are produced through a simple and inexpensive process. The time required to generate aptamers is comparatively short.
Aptamers have significant benefits over antibodies such as superior affinity, easy modification, better stability, smaller size, high productivity, easy immobilization, and specificity to the target. These advantages make aptamers a preferred choice over antibodies. This is driving the aptamer market growth.
Aptamer conjugates are formed by hybridization of aptamers with nucleic acid drugs. This makes aptamer an efficient carrier and precise deliverer of nucleic acid to targeted cells. Furthermore, aptamer can be used under non-physiological conditions for analytical purposes.
Development of novel diagnostic procedures and creation of new diagnostic tests are augmenting the applications of aptamers in targeted drug delivery. Market dynamics of aptamers in cancer diagnostics are growing owing to the rise in incidence of cancer across the globe.
Aptamers are extensively employed in the treatment of chronic diseases, as they help with protein production monitoring, purification, and quality control required during treatments. Thus, growth in prevalence of chronic diseases across the globe is fueling market statistics.
According to a study conducted by the World Health Organization, around 74% of global deaths (approximately 41 million people) are caused by Noncommunicable Diseases (NCDs) each year. Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including kidney disease deaths caused by diabetes).
Healthcare organizations are investing significantly in research and development activities to enhance their product portfolio. Growth in healthcare facilities and availability of advanced treatments for chronic diseases are bolstering the aptamer market revenue.
Increase in approvals for advanced technologies in aptamer therapies is encouraging healthcare professionals to investigate and innovate more efficient aptamers. Furthermore, rise in number of clinical trials conducted to develop aptamer-based therapeutics is augmenting the aptamer market size.
Thus, growth in awareness about the advantages of aptamer-based therapies to cure diseases is driving the demand for aptamers.
North America is likely to hold the largest aptamer market share during the forecast period. Availability of advanced healthcare facilities is fostering market expansion in the region. Increase in prevalence of chronic diseases and rise in focus of research laboratories in the aptamer field are creating lucrative aptamer industry opportunities for companies operating in North America.
Growth in investment in R&D to develop advanced treatments for chronic and cardiovascular diseases and ensure a faster recovery rate is also projected to boost the demand for aptamers in North America.
Leading market players are implementing strategies such as collaborations and partnerships to introduce advanced therapies. They are striving to increase their product portfolio in order to strengthen their market position. Companies are also aiming to secure funding from investors in order to further explore the potential of aptamers in the healthcare sector.
Some of the prominent companies in the aptamer industry are AM Biotech., Aptagen, LLC, Aptamer Group, Aptamer Science, Inc., Pfizer Inc., Base Pair Biotechnologies, CD Genomics, NeoVentures Biotechnology Inc., NAXXON Pharma, Aptus Biotech, and TriLink Bio Technologies, LLC.
These players have been profiled in the aptamer market report based on parameters such as financial overview, company overview, product portfolio, business strategies, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 1.7 Bn |
| Market Forecast (Value) in 2031 | US$ 7.0 Bn |
| Growth Rate (CAGR) | 16.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Tons | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 1.7 Bn in 2022
It is projected to register a CAGR of 16.5% from 2023 to 2031
Benefits of aptamer over antibodies and increase in R&D investments
North America was the most lucrative region in 2022
AM Biotech, Aptagen, LLC, Aptamer Group, Aptamer Science, Inc., Pfizer Inc., Base Pair Biotechnologies, CD Genomics, NeoVentures Biotechnology Inc., NAXXON Pharma, Aptus Biotech, and TriLink Bio Technologies, LLC
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Aptamer Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Aptamer Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Aptamer Market Analysis and Forecast, by Material
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Material, 2023–2031
6.3.1. Nucleic Acid Aptamer
6.3.2. Peptide Aptamer
6.4. Market Attractiveness, by Material
7. Aptamer Market Analysis and Forecast, by Application
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2023–2031
7.3.1. Research
7.3.2. Diagnostic
7.3.3. Therapeutics
7.3.4. Others
7.3.5. 7.4 Market Attractiveness, by Application
8. Global Aptamer Market Analysis and Forecast, by Technique
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Technique, 2023–2031
8.3.1. SELEX Technique
8.3.2. Others (MARAS, etc.)
8.4. Market Attractiveness, by Technique
9. Global Aptamer Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Aptamer Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Material, 2023–2031
10.2.1. Nucleic Acid Aptamer
10.2.2. Peptide Aptamer
10.3. Market Attractiveness, by Material
10.4. Market Value Forecast, by Application, 2023–2031
10.4.1. Research
10.4.2. Diagnostic
10.4.3. Therapeutics
10.4.4. Others
10.5. Market Attractiveness, by Application
10.6. Market Value Forecast, by Technique, 2023–2031
10.6.1. SELEX Technique
10.6.2. Others (MARAS, etc.)
10.7. Market Attractiveness, by Technique
10.8. Market Value Forecast, by Country, 2022–2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Material
10.9.2. By Application
10.9.3. By Technique
10.9.4. By Country
11. Europe Aptamer Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Material, 2023–2031
11.2.1. Nucleic Acid Aptamer
11.2.2. Peptide Aptamer
11.3. Market Attractiveness, by Material
11.4. Market Value Forecast, by Application, 2023–2031
11.4.1. Research
11.4.2. Diagnostic
11.4.3. Therapeutics
11.4.4. Others
11.5. Market Attractiveness, by Application
11.6. Market Value Forecast, by Technique, 2023–2031
11.6.1. SELEX Technique
11.6.2. Others (MARAS, etc.)
11.7. Market Attractiveness, by Technique
11.8. Market Value Forecast, by Country/Sub-region, 2022–2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Material
11.9.2. By Application
11.9.3. By Technique
11.9.4. By Country/Sub-region
12. Asia Pacific Aptamer Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Material, 2023–2031
12.2.1. Nucleic Acid Aptamer
12.2.2. Peptide Aptamer
12.3. Market Attractiveness, by Material
12.4. Market Value Forecast, by Application, 2023–2031
12.4.1. Research
12.4.2. Diagnostic
12.4.3. Therapeutics
12.4.4. Others
12.5. Market Attractiveness, by Application
12.6. Market Value Forecast, by Technique, 2023–2031
12.6.1. SELEX Technique
12.6.2. Others (MARAS, etc.)
12.7. Market Attractiveness, by Technique
12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Material
12.9.2. By Application
12.9.3. By Technique
12.9.4. By Country/Sub-region
13. Latin America Aptamer Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Material, 2023–2031
13.2.1. Nucleic Acid Aptamer
13.2.2. Peptide Aptamer
13.3. Market Attractiveness, by Material
13.4. Market Value Forecast, by Application, 2023–2031
13.4.1. Research
13.4.2. Diagnostic
13.4.3. Therapeutics
13.4.4. Others
13.5. Market Attractiveness, by Application
13.6. Market Value Forecast, by Technique, 2023–2031
13.6.1. SELEX Technique
13.6.2. Others (MARAS, etc.)
13.7. Market Attractiveness, by Technique
13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Material
13.9.2. By Application
13.9.3. By Technique
13.9.4. By Country/Sub-region
14. Middle East & Africa Aptamer Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Material, 2023–2031
14.2.1. Nucleic Acid Aptamer
14.2.2. Peptide Aptamer
14.3. Market Attractiveness, by Material
14.4. Market Value Forecast, by Application, 2023–2031
14.4.1. Research
14.4.2. Diagnostic
14.4.3. Therapeutics
14.4.4. Others
14.5. Market Attractiveness, by Application
14.6. Market Value Forecast, by Technique, 2023–2031
14.6.1. SELEX Technique
14.6.2. Others (MARAS, etc.)
14.7. Market Attractiveness, by Technique
14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Material
14.9.2. By Application
14.9.3. By Technique
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AM Biotech
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Aptagen, LLC
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Aptamer Group
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Aptamer Science, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Pfizer Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Base Pair Biotechnologies
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. CD Genomics
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. NeoVentures Biotechnology Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. NAXXON Pharma
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Aptus Biotech
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. TriLink Bio Technologies, LLC
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
List of Tables
Table 1: Global Aptamer Market Value (US$ Mn) Forecast, by Material, 2023–2031
Table 2: Global Aptamer Market Value (US$ Mn) Forecast, by Application, 2023–2031
Table 3: Global Aptamer Market Value (US$ Mn) Forecast, by Technique, 2023–2031
Table 4: Global Aptamer Market Value (US$ Mn) Forecast, by Region, 2023–2031
Table 5: North America Aptamer Market Value (US$ Mn) Forecast, by Country, 2023–2031
Table 6: North America Aptamer Market Value (US$ Mn) Forecast, by Material, 2023–2031
Table 7: North America Aptamer Market Value (US$ Mn) Forecast, by Application, 2023–2031
Table 8: North America Aptamer Market Value (US$ Mn) Forecast, by Technique, 2023–2031
Table 9: Europe Aptamer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Europe Aptamer Market Value (US$ Mn) Forecast, by Material, 2023–2031
Table 11: Europe Aptamer Market Value (US$ Mn) Forecast, by Application, 2023–2031
Table 12: Europe Aptamer Market Value (US$ Mn) Forecast, by Technique 2023–2031
Table 13: Asia Pacific Aptamer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Asia Pacific Aptamer Market Value (US$ Mn) Forecast, by Material, 2023–2031
Table 15: Asia Pacific Aptamer Market Value (US$ Mn) Forecast, by Application, 2023–2031
Table 16: Asia Pacific Aptamer Market Value (US$ Mn) Forecast, by Technique, 2023–2031
Table 17: Latin America Aptamer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 18: Latin Americaa Aptamer Market Value (US$ Mn) Forecast, by Material, 2023–2031
Table 19: Latin America Aptamer Market Value (US$ Mn) Forecast, by Application, 2023–2031
Table 20: Latin America Aptamer Market Value (US$ Mn) Forecast, by Technique 2023–2031
Table 21: Middle East & Africa Aptamer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 22: Middle East & Africa Aptamer Market Value (US$ Mn) Forecast, by Material, 2023–2031
Table 23: Middle East & Africa Aptamer Market Value (US$ Mn) Forecast, by Application, 2023–2031
Table 24: Middle East & Africa Aptamer Market Value (US$ Mn) Forecast, by Technique 2023–2031
List of Figures
Figure 1: Global Aptamer Market Value (US$ Mn) Forecast, 2023–2031
Figure 2: Global Aptamer Market Value Share, by Material, 2022
Figure 3: Global Aptamer Market Value Share, by Application, 2022
Figure 4: Global Aptamer Market Value Share, by Technique, 2022
Figure 5: Global Aptamer Market Value Share Analysis, by Material, 2022 and 2031
Figure 6: Global Aptamer Market Attractiveness Analysis, by Material, 2023–2031
Figure 7: Global Aptamer Market Value Share Analysis, by Application, 2022 and 2031
Figure 8: Global Aptamer Market Attractiveness Analysis, by Application, 2023–2031
Figure 9: Global Aptamer Market Value Share Analysis, by Technique, 2022 and 2031
Figure 10: Global Aptamer Market Attractiveness Analysis, by Technique 2023–2031
Figure 11: Global Aptamer Market Value Share Analysis, by Region, 2022 and 2031
Figure 12: Global Aptamer Market Attractiveness Analysis, by Region, 2023–2031
Figure 13: North America Aptamer Market Value (US$ Mn) Forecast, 2023–2031
Figure 14: North America Aptamer Market Value Share Analysis, by Country, 2022 and 2031
Figure 15: North America Aptamer Market Attractiveness Analysis, by Country, 2023–2031
Figure 16: North America Aptamer Market Value Share Analysis, by Material, 2022 and 2031
Figure 17: North America Aptamer Market Attractiveness Analysis, by Material, 2023–2031
Figure 18: North America Aptamer Market Value Share Analysis, by Application, 2022 and 2031
Figure 19: North America Aptamer Market Attractiveness Analysis, by Application, 2023–2031
Figure 20: North America Aptamer Market Value Share Analysis, by Technique, 2022 and 2031
Figure 21: North America Aptamer Market Attractiveness Analysis, by Technique 2023–2031
Figure 22: Europe Aptamer Market Value (US$ Mn) Forecast, 2023–2031
Figure 23: Europe Aptamer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 24: Europe Aptamer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 25: Europe Aptamer Market Value Share Analysis, by Material, 2022 and 2031
Figure 26: Europe America Aptamer Market Attractiveness Analysis, by Material, 2023–2031
Figure 27: Europe Aptamer Market Value Share Analysis, by Application, 2022 and 2031
Figure 28: Europe Aptamer Market Attractiveness Analysis, by Application, 2023–2031
Figure 29: Europe Aptamer Market Value Share Analysis, by Technique, 2022 and 2031
Figure 30: Europe Aptamer Market Attractiveness Analysis, by Technique 2023–2031
Figure 31: Asia Pacific Aptamer Market Value (US$ Mn) Forecast, 2023–2031
Figure 32: Asia Pacific Aptamer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Asia Pacific Aptamer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 34: Asia Pacific Aptamer Market Value Share Analysis, by Material, 2022 and 2031
Figure 35: Asia Pacific America Aptamer Market Attractiveness Analysis, by Material, 2023–2031
Figure 36: Asia Pacific Aptamer Market Value Share Analysis, by Application, 2022 and 2031
Figure 37: Asia Pacific Aptamer Market Attractiveness Analysis, by Application, 2023–2031
Figure 38: Asia Pacific Aptamer Market Value Share Analysis, by Technique, 2022 and 2031
Figure 39: Asia Pacific Aptamer Market Attractiveness Analysis, by Technique 2023–2031
Figure 40: Latin America Aptamer Market Value (US$ Mn) Forecast, 2023–2031
Figure 41: Latin America Aptamer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Latin America Aptamer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Latin America Aptamer Market Value Share Analysis, by Material, 2022 and 2031
Figure 44: Latin America Aptamer Market Attractiveness Analysis, by Material, 2023–2031
Figure 45: Latin America Aptamer Market Value Share Analysis, by Application, 2022 and 2031
Figure 46: Latin America Aptamer Market Attractiveness Analysis, by Application, 2023–2031
Figure 47: Latin America Aptamer Market Value Share Analysis, by Technique, 2022 and 2031
Figure 48: Latin America Aptamer Market Attractiveness Analysis, by Technique, 2023–2031
Figure 49: Middle East & Africa Aptamer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 50: Middle East & Africa Aptamer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 51: Middle East & Africa America Aptamer Market Value Share Analysis, by Material, 2023–2031
Figure 52: Middle East & Africa America Aptamer Market Attractiveness Analysis, by Material, 2023–2031
Figure 53: Middle East & Africa Aptamer Market Value Share Analysis, by Technique, 2022 and 2031
Figure 54: Middle East & Africa Aptamer Market Attractiveness Analysis, by Technique 2023–2031
Figure 55: Global Aptamer Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Aptamer Market
*86 figures and 60 tables includes